In this episode, we explore a translational study led by Sato and colleagues on the oral STAT3 inhibitor YHO-1701 and its efficacy in treating ovarian cancer. The study highlights YHO-1701's ability to inhibit tumor growth in various ovarian cancer cell lines and patient-derived cells, as well as its potential to reduce peritoneal metastasis in mouse models. By targeting the STAT3 pathway and downregulating the anti-apoptotic protein survivin, YHO-1701 promotes apoptosis in cancer cells. Tune in to learn about the implications of these findings for future ovarian cancer therapies.